News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mallinckrodt Inc. Announces Agreement With Xanodyne Pharmaceuticals, Inc. to Purchase Roxicodone®


8/23/2012 10:34:56 AM

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has entered into an agreement with Xanodyne Pharmaceuticals to purchase Roxicodone® (oxycodone hydrochloride tablets USP) in 5, 15 and 30 mg dosage strengths. Roxicodone, currently marketed in the United States, is an immediate release formulation of oxycodone indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. With this agreement, Mallinckrodt acquires all rights to the Roxicodone New Drug Application (NDA). No financial details were disclosed.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES